T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Summary:
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples
Description of Technology:
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.
Immunogens for Use in a High Efficacy HIV Vaccine
Summary:
The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
Description of Technology:
Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells.
Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection
Summary:
The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.
CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles
Description of Technology:
Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts.
3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases
Summary:
The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2
IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors
Description of Technology:
Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.
Size-dependent brain distribution of macromolecular drug delivery platform
Summary:
The NCI seeks research co-development partners and/or licensees for a selective polylysine succinylated (PLS) drug delivery platform.